These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 19005479)

  • 1. A dose-dependent tug of war involving the NPM1 leukaemic mutant, nucleophosmin, and ARF.
    Bolli N; De Marco MF; Martelli MP; Bigerna B; Pucciarini A; Rossi R; Mannucci R; Manes N; Pettirossi V; Pileri SA; Nicoletti I; Falini B
    Leukemia; 2009 Mar; 23(3):501-9. PubMed ID: 19005479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Born to be exported: COOH-terminal nuclear export signals of different strength ensure cytoplasmic accumulation of nucleophosmin leukemic mutants.
    Bolli N; Nicoletti I; De Marco MF; Bigerna B; Pucciarini A; Mannucci R; Martelli MP; Liso A; Mecucci C; Fabbiano F; Martelli MF; Henderson BR; Falini B
    Cancer Res; 2007 Jul; 67(13):6230-7. PubMed ID: 17616680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications.
    Falini B; Bolli N; Liso A; Martelli MP; Mannucci R; Pileri S; Nicoletti I
    Leukemia; 2009 Oct; 23(10):1731-43. PubMed ID: 19516275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Curious Novel Combination of
    Venanzi A; Rossi R; Martino G; Annibali O; Avvisati G; Mameli MG; Sportoletti P; Tiacci E; Falini B; Martelli MP
    Genes (Basel); 2021 Sep; 12(9):. PubMed ID: 34573408
    [No Abstract]   [Full Text] [Related]  

  • 5. Delocalization and destabilization of the Arf tumor suppressor by the leukemia-associated NPM mutant.
    Colombo E; Martinelli P; Zamponi R; Shing DC; Bonetti P; Luzi L; Volorio S; Bernard L; Pruneri G; Alcalay M; Pelicci PG
    Cancer Res; 2006 Mar; 66(6):3044-50. PubMed ID: 16540653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML.
    Falini B; Bolli N; Shan J; Martelli MP; Liso A; Pucciarini A; Bigerna B; Pasqualucci L; Mannucci R; Rosati R; Gorello P; Diverio D; Roti G; Tiacci E; Cazzaniga G; Biondi A; Schnittger S; Haferlach T; Hiddemann W; Martelli MF; Gu W; Mecucci C; Nicoletti I
    Blood; 2006 Jun; 107(11):4514-23. PubMed ID: 16455950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a novel nucleophosmin-interaction motif in the tumor suppressor p14arf.
    Luchinat E; Chiarella S; Franceschini M; Di Matteo A; Brunori M; Banci L; Federici L
    FEBS J; 2018 Mar; 285(5):832-847. PubMed ID: 29283500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions of the natural product (+)-avrainvillamide with nucleophosmin and exportin-1 Mediate the cellular localization of nucleophosmin and its AML-associated mutants.
    Mukherjee H; Chan KP; Andresen V; Hanley ML; Gjertsen BT; Myers AG
    ACS Chem Biol; 2015 Mar; 10(3):855-63. PubMed ID: 25531824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytoplasmic localization of NPM in myeloid leukemias is dictated by gain-of-function mutations that create a functional nuclear export signal.
    Mariano AR; Colombo E; Luzi L; Martinelli P; Volorio S; Bernard L; Meani N; Bergomas R; Alcalay M; Pelicci PG
    Oncogene; 2006 Jul; 25(31):4376-80. PubMed ID: 16501600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute myeloid leukemia with mutated nucleophosmin (NPM1): molecular, pathological, and clinical features.
    Falini B
    Cancer Treat Res; 2010; 145():149-68. PubMed ID: 20306250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New insights into the biology of acute myeloid leukemia with mutated NPM1.
    Brunetti L; Gundry MC; Goodell MA
    Int J Hematol; 2019 Aug; 110(2):150-160. PubMed ID: 30632059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias.
    Falini B; Nicoletti I; Bolli N; Martelli MP; Liso A; Gorello P; Mandelli F; Mecucci C; Martelli MF
    Haematologica; 2007 Apr; 92(4):519-32. PubMed ID: 17488663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia.
    Ovcharenko D; Stölzel F; Poitz D; Fierro F; Schaich M; Neubauer A; Kelnar K; Davison T; Müller-Tidow C; Thiede C; Bornhäuser M; Ehninger G; Brown D; Illmer T
    Exp Hematol; 2011 Oct; 39(10):1030-1042.e7. PubMed ID: 21784052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant cytoplasmic expression of C-terminal-truncated NPM leukaemic mutant is dictated by tryptophans loss and a new NES motif.
    Falini B; Albiero E; Bolli N; De Marco MF; Madeo D; Martelli M; Nicoletti I; Rodeghiero F
    Leukemia; 2007 Sep; 21(9):2052-4; author reply 2054; discussion 2055-6. PubMed ID: 17637816
    [No Abstract]   [Full Text] [Related]  

  • 15. Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives.
    Falini B; Sportoletti P; Martelli MP
    Curr Opin Oncol; 2009 Nov; 21(6):573-81. PubMed ID: 19770764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of nucleophosmin leukaemic mutants in B and T cells from AML with NPM1 mutations: implications for the cell of origin of NPMc+ AML.
    Martelli MP; Manes N; Pettirossi V; Liso A; Pacini R; Mannucci R; Zei T; Bolli N; di Raimondo F; Specchia G; Nicoletti I; Martelli MF; Falini B
    Leukemia; 2008 Jan; 22(1):195-8. PubMed ID: 17637812
    [No Abstract]   [Full Text] [Related]  

  • 17. Leukemia-Associated Mutations in Nucleophosmin Alter Recognition by CRM1: Molecular Basis of Aberrant Transport.
    Arregi I; Falces J; Olazabal-Herrero A; Alonso-Mariño M; Taneva SG; Rodríguez JA; Urbaneja MA; Bañuelos S
    PLoS One; 2015; 10(6):e0130610. PubMed ID: 26091065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia.
    Nabbouh AI; Hleihel RS; Saliba JL; Karam MM; Hamie MH; Wu HJM; Berthier CP; Tawil NM; Bonnet PA; Deleuze-Masquefa C; El Hajj HA
    Cancer; 2017 May; 123(9):1662-1673. PubMed ID: 28055106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features.
    Falini B; Nicoletti I; Martelli MF; Mecucci C
    Blood; 2007 Feb; 109(3):874-85. PubMed ID: 17008539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia.
    Falini B; Martelli MP; Bolli N; Bonasso R; Ghia E; Pallotta MT; Diverio D; Nicoletti I; Pacini R; Tabarrini A; Galletti BV; Mannucci R; Roti G; Rosati R; Specchia G; Liso A; Tiacci E; Alcalay M; Luzi L; Volorio S; Bernard L; Guarini A; Amadori S; Mandelli F; Pane F; Lo-Coco F; Saglio G; Pelicci PG; Martelli MF; Mecucci C
    Blood; 2006 Sep; 108(6):1999-2005. PubMed ID: 16720834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.